News
Clinical Trials Arena on MSN25d
Eli Lilly’s lepodisiran cuts lipoprotein(a) by 93.9% in Phase II trialThe Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback